Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

107P - Eradication of osteosarcoma cells with methioninase combined with ethionine is associated with down-regulation of beta catenin/cyclin-D1

Date

15 Mar 2024

Session

Poster Display session

Presenters

Yusuke Aoki

Citation

Annals of Oncology (2024) 9 (suppl_2): 1-32. 10.1016/esmoop/esmoop102441

Authors

Y. Aoki1, Y. Tome1, H. Oshiro1, R. Katsuki1, S. Miyagi1, K. Nishida1, R. Hoffman2

Author affiliations

  • 1 Department Of Orthopedic Surgery, University of the Ryukyus, 903-0125 - Okinawa/JP
  • 2 Department Of Surgery, University of California San Diego - UCSD, 92093 - La Jolla/US

Resources

This content is available to ESMO members and event participants.

Abstract 107P

Background

Methionine (MET) addiction is a fundamental and general hallmark of cancer cells, including osteosarcoma cells, which is termed the Hoffman effect, due to overuse of exogenous MET for highly increased transmethylation reactions. The beta catenin/cyclin-D1 pathway is associated with tumor progression, including osteosarcoma. In the present study, we targeted MET addiction with the combination of methioninase (rMETase), and the MET analogue, ethionine (ETH), to eradicate osteosarcoma cells and down regulate beta catenin/cyclin-D1 pathway.

Methods

The efficacy of rMETase, ETH, or the combination of both rMETase and ETH on cell viability was compared with the WST-8 assay in 143B osteosarcoma cells and Hs27 normal human foreskin fibroblasts. The expression of beta catenin and cyclin-D1 was determined with Western immunoblotting and compared in 143B cells treated with/without rMETase, ETH, or the combination of both rMETase and ETH.

Results

143B cells were more sensitive toboth rMETase and ETH than Hs 27 cells, with the following IC50: rMETase (143B: 0.2 U/ml, Hs27: 1.17 U/ml); ETH (143B: 0.29 mg/ml, Hs27: 0.82 mg/ml). 143B cells were synergistically eradicated by the combination of rMETase and ETH (p<0.001). In contrast, Hs27 fibroblasts were relatively resistant to the combination. The expression of both beta catenin and cyclin-D1 was significantly down-regulated by the combination of rMETase and ETH in 143B cells (p<0.001, p=0.04, respectively).

Conclusions

In the present study, the synergistic combination efficacy of rMETase and ETH on osteosarcoma cells was shown, in contrast to normal fibroblasts, which were relatively resistant. The combination of rMETase and ETH down regulated the expression of both beta catenin and cyclin-D1 in osteosarcoma cells, which may be epigenetically dysregulated via suppression of transmethylation reactions by the combination therapy. The present results indicate the combination of rMETase and ETH can be a potential future clinical strategy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.